A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other
A phase 1/2 trial of Pembrolizumab, Trastuzumab, Trastuzumab emtansine in ovarian cancer and melanoma, run by Ascendis Pharma Oncology Division A/S, active and no longer recruiting.
Overview
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies is a phase 1/2 interventional study registered as NCT05081609 by Ascendis Pharma Oncology Division A/S, with 320 participants enrolled, started 2022-01-11 and due to reach its primary completion in 2027-08. Interventions recorded: TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug, TransCon TLR7/8 Agonist, Surgery. Conditions listed: Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Shares Trastuzumab emtansine, Trastuzumab.
- TrialBasket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Shares Trastuzumab, Cervical cancer, Non-small-cell lung cancer.
- TrialA Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Shares Trastuzumab emtansine, Trastuzumab.
- IdeaPooled procurement and voluntary licensing for essential cancer medicines in low-income countries
Shares Trastuzumab, Pembrolizumab.
- TrialStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Shares Trastuzumab, Pembrolizumab.
- IdeaA public fund for trials that test less treatment
Shares Trastuzumab, Pembrolizumab.
- TrialBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People Wit
Shares Trastuzumab emtansine, Trastuzumab.
- IdeaHome infusion and local blood draws for trial drugs after the first cycles
Shares Trastuzumab, Pembrolizumab.